Results 91 to 100 of about 1,486,273 (317)

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients : analysis of >4,500 patients from four German randomized breast cancer trials [PDF]

, 2008
Introduction: Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases.
Kümmel, Sherko, Sibylle Loibl, Gunter von Minckwitz, Kuemmel, Sherko, Valentina Nekljudova, Marion Kiechle, Elling, Dirk, Holm Eggemann, Harald Sommer, Janni, Wolfgang, Sommer, Harald, Wolfgang Janni, Loibl, Sibylle, Nadia Harbeck, Manfred Kaufmann, Harbeck, Nadia, Nekljudova, Valentina, Minckwitz, Gunter von, Sherko Kümmel, Kiechle, Marion, Kaufmann, Manfred, Eggemann, Holm, Dirk Elling   +22 more
core   +2 more sources

Antibiotic dosing in obesity: size does matter? [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2017
Currently, from 15 to 50% of the population in the developed countries has obesity. Overall, patients with obesity have a higher risk of infection; they are more likely to develop infectious complications after surgical interventions and have a higher ...
Andreeva I.V., Stetsiouk O.U., Kozlov R.S.   +2 more
doaj  

Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation

Scientific Reports, 2017
Podoplanin/Aggrus, known as a platelet aggregation-inducing factor, is frequently overexpressed in lung squamous cell carcinomas (LSCC) and glioblastomas among other tumours, and its expression has been reported to be correlated with poor prognosis ...
Kenichi Miyata, Ai Takemoto, Sakae Okumura, Makoto Nishio, Naoya Fujita   +4 more
doaj   +1 more source

Preoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinoma

Kaohsiung Journal of Medical Sciences, 2013
Preoperative elevation of serum C-reactive protein (CRP) is reportedly associated with poor prognosis in several types of cancer. This study investigated the role of serum CRP as a prognostic factor in early-stage esophageal squamous cell carcinoma (ESCC)
Zheng-Bo Song, Bao-Chai Lin, Bo Li, Chun-Xiao He, Bei-Bei Zhang, Lan Shao, Yi-Ping Zhang   +6 more
doaj   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck [PDF]

, 2005
Objective: The purpose of this pilot study was to evaluate the feasibility and toxicity of concurrent chemotherapy with vinorelbine and mitomycin C in combination with accelerated radiotherapy (RT) in patients with locally advanced cancer of the head and
Wilkowski, R., Schalhorn, A., Dellian, M., Dühmke, Eckhart, Pachmann, S., Schymura, B.   +5 more
core   +1 more source

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

npj Precision Oncology
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge.
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama   +15 more
doaj   +1 more source

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

Thoracic Cancer, 2020
Background Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK‐positive NSCLCs. However, the emergence of acquired resistance is inevitable.
Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama   +11 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source